Feed AXSM
AX

Axsome Therapeutics

AXSM · NASDAQ

$204.07 -5.09% (-$10.95)
1M -5.64%
Market Cap $11.1B
P/E Ratio -
Div. Yield -
ROE 255.60%

Bulios Fair Price

$188.5

7.6% downside

Trenutna cena

$204.07

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica AXSM trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Weak
3/9
Valuation
0 /100
Expensive
P/B 133.79x
P/S 14.35x
PEG N/A
Growth
78 /100
Growing
Book val. growth 6.94%
Rev. growth 133.68%
FCF growth N/A
Profitability
20 /100
Weak
FCF margin 9.19%
Op. margin 24.28%
Gross margin 93.24%
Quality
13 /100
Poor
Asset turnover 1.02x
ROA 25.17%
ROIC 50.88%
Debt
16 /100
High
Current ratio 1.43x
Int. coverage -37.09x
Debt/Equity 2.63x
Stability
45 /100
Moderate
Profitable years 0
EPS volatility 30.42%
Beta 0.60x

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o AXSM
Online

O podjetju

Axsome Therapeutics, Inc. (AXSM) is a biotechnology company focused on the development and commercialization of innovative drugs for the treatment of various neurologic and psychiatric disorders. The company targets therapeutic areas such as depression, migraines, Alzheimer's disease, and other neurological conditions that have a significant impact on human health. Axsome Therapeutics aims to improve the quality of life for patients by offering novel and effective treatment options. With active research and clinical trials, the company has a promising pipeline of drugs that can have a positive impact on healthcare and the medical industry. Investing in Axsome Therapeutics, Inc. (AXSM) shares can be an attractive choice for investors who follow the biotechnology and pharmaceutical sectors and seek a company with the potential for significant growth and innovative treatment approaches.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Biotechnology

CEO

Herriot Tabuteau

Employees

1,346

Headquarters

New York City

Prihajajoči dogodki

02 NOV.

Earnings

Upcoming earnings report

47d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.